『New Malaria Vaccines Cut Cases in Half But Face Growing Drug Resistance and Supply Challenges』のカバーアート

New Malaria Vaccines Cut Cases in Half But Face Growing Drug Resistance and Supply Challenges

New Malaria Vaccines Cut Cases in Half But Face Growing Drug Resistance and Supply Challenges

無料で聴く

ポッドキャストの詳細を見る
# Malaria Vaccines Show Promise Despite Growing Challenges The global fight against malaria is entering a critical phase with newly approved vaccines offering hope, yet experts warn that vaccination alone cannot solve the crisis as resistance to treatments and insecticides continues to spread. Two breakthrough malaria vaccines, Mosquirix and R21, have demonstrated significant impact since their WHO approval in 2021 and 2023. According to Rotary International, these vaccines have reduced malaria cases in children by more than 50 percent during the first year after the initial series of three doses, with a fourth booster dose recommended after one year to prolong protection. The R21 vaccine, developed by Oxford and produced at scale by the Serum Institute of India, has proven particularly valuable for African nations due to its low cost and ease of production. According to information from Tropical Health Matters, the R21 vaccine provides up to 80 percent protection against malaria when three initial doses are followed by a booster. Kenya has emerged as a success story for malaria vaccine implementation. Since 2019, the country has made significant improvements in death rates and hospitalizations from malaria in young children through the Malaria Vaccine Implementation Programme involving children under 2 years old. Ghana also became the first country to approve the R21 vaccine, with regulators moving swiftly based on trial data showing its safety and effectiveness. However, challenges threaten to undermine these advances. A malaria expert at Johns Hopkins University, Jane Carlton, warned that vaccines alone will not be enough to stop the spread of malaria as cases and deaths continue rising globally. According to the World Health Organization, there were 282 million malaria cases worldwide in 2024, up by about 9 million from 2023, with deaths rising to 610,000 from 598,000 the previous year. Carlton highlighted several alarming trends. Resistance to artemisinin-based medicines, the main treatment for malaria, has spread to at least eight African countries. The WHO has also identified growing resistance among mosquitoes to insecticides used in bed nets. Additionally, new strains of the malaria parasite are becoming harder to detect because they can evade standard rapid diagnostic tests, and a mosquito species resistant to common insecticides, Anopheles stephensi, is spreading. Experts stress that vaccines work best when combined with complementary measures such as bed nets, medicines, and mosquito control. A promising new development is Ganaplacide, also known as GanLum, described as the first new class of malaria drug in more than 25 years. According to information from DelveInsight's malaria pipeline report, multiple pharmaceutical companies including Novartis and Merck are actively developing new antimalarial treatments, with several combination therapies and novel approaches currently in clinical trials. The rollout of malaria vaccines f This content was created in partnership and with the help of Artificial Intelligence AI.
adbl_web_anon_alc_button_suppression_c
まだレビューはありません